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Abstract
The development of computational models for simulating tumor growth and response to treatment has gained significant
momentum during the last few decades. At the dawn of the era of personalized medicine, providing insight into complex
mechanisms involved in cancer and contributing to patient-specific therapy optimization constitute particularly inspiring
pursuits. The in silico oncology community is facing the great challenge of effectively translating simulation models into
clinical practice, which presupposes a thorough sensitivity analysis, adaptation and validation process based on real clinical
data. In this paper, the behavior of a clinically-oriented, multiscale model of solid tumor response to chemotherapy is
investigated, using the paradigm of nephroblastoma response to preoperative chemotherapy in the context of the SIOP/
GPOH clinical trial. A sorting of the model’s parameters according to the magnitude of their effect on the output has
unveiled the relative importance of the corresponding biological mechanisms; major impact on the result of therapy is
credited to the oxygenation and nutrient availability status of the tumor and the balance between the symmetric and
asymmetric modes of stem cell division. The effect of a number of parameter combinations on the extent of chemotherapy-
induced tumor shrinkage and on the tumor’s growth rate are discussed. A real clinical case of nephroblastoma has served as
a proof of principle study case, demonstrating the basics of an ongoing clinical adaptation and validation process. By using
clinical data in conjunction with plausible values of model parameters, an excellent fit of the model to the available medical
data of the selected nephroblastoma case has been achieved, in terms of both volume reduction and histological
constitution of the tumor. In this context, the exploitation of multiscale clinical data drastically narrows the window of
possible solutions to the clinical adaptation problem.
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Introduction
The last few decades have witnessed an increased interest of the
scientific community into the development of computational
models for simulating tumor growth and response to treatment
[1–3]. At the beginning of the era of personalized medicine,
sophisticated multiscale models yield valuable quantitative insights
into complex mechanisms involved in cancer and may ultimately
contribute to patient-specific therapy optimization.
The major modeling approaches can be distinguished into
predominantly continuous and predominantly discrete models.
Predominantly continuous models rely primarily on differential
equations to describe processes such as diffusion of molecules,
changes in tumor cell density and invasion of tumor cells into the
surrounding tissue [4–9]. Predominantly discrete modeling
considers several discrete states in which cells may be found and
possible transitions between them, governed by ‘‘decision
calculators’’, such as cytokinetic diagrams and agent-based
techniques [10–18]. Discrete models are usually represented by
cellular automata of several forms and variable complexity (grids
of cells or groups of cells, in which a finite number of states and a
set of evolution and interaction rules are defined). Due to the
hypercomplexity of cancer-related topics, each modeling approach
is intrinsically able to satisfactorily address only some of the aspects
of this multifaceted problem. Ultimate goal of clinically-oriented
cancer simulation models is their eventual translation into clinical
practice, which entails a) thorough sensitivity analyses, in order to
both comprehend and validate their behavior, and at the same
time gain further insight into the simulated mechanisms, in a more
quantitative way, and b) an adaptation and validation process
based on real clinical data.
This paper investigates the behavior of an actual clinical trial-
driven model simulating the response of nephroblastoma tumors
to preoperative chemotherapy. Nephroblastoma (also termed
Wilms’ tumor) is the most common renal malignancy in children
[19,20]. Indicative results of an in-depth sensitivity analysis of the
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17594model regarding the effect of critical mechanisms involved in the
dynamics of the biological system are presented, along with a proof
of principle, successful adaptation study to an actual clinical
Wilms’ tumor case, drawn from the SIOP 2001/GPOH trial
[21,22]. The model is in the process of clinical adaptation and
validation within the framework of the EC-funded project
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General features of the simulation model
The model is a predominantly discrete, clinically-oriented
multiscale cancer model of solid tumor response to chemotherapy
[23,24], stemming from previous work of the In Silico Oncology
Group (ISOG), National Technical University of Athens (NTUA).
A ‘‘top-down’’ simulation approach is formulated [25,26]; the
method starts from the macroscopic imaging data (a high
biocomplexity level) and proceeds towards lower biocomplexity
levels. When there is a need for an upwards movement in the
biocomplexity scales, a summary of the available information
pertaining to the previous lower level is used. The clinical
orientation of the model has been a fundamental guiding principle
throughout its development. Available medical data can be
exploited, in order to strengthen patient-individualized modeling.
The model is under continuous refinement in the framework of
clinical trials.
Basic algorithmic notions
The following five categories (or ‘‘equivalence classes’’) of
cancer cells are considered in the model: stem cells (cells of
unlimited mitotic potential), LIMP cells (LImited Mitotic Potential
or committed progenitor cells, which can perform a limited
number of mitoses before terminal differentiation), terminally
differentiated cells, apoptotic and necrotic cells. The various cell
cycle phases (G1, S, G2, M) and the dormant (G0) phase constitute
subclasses in which stem or LIMP cells may reside. Figure 1
depicts the developed cytokinetic model, which incorporates
several biological phenomena that take place at the cellular level:
N Cycling of proliferating cells through the successive cell cycle
phases.
N Symmetric and asymmetric modes of stem cell division.
N Terminal differentiation of committed progenitor cells after a
number of mitotic divisions.
N Transition of proliferating cells to the dormant phase due to
inadequate supply of oxygen and nutrients.
N Reentering of dormant cells into the active cell cycle due to
local restoration of oxygen and nutrient supplies.
N Cell death through spontaneous apoptosis.
N Cell death through necrosis (due to prolonged oxygen and
nutrients’ shortage).
N Cell death due to chemotherapy-induced apoptosis.
Table 1 presents the corresponding tumor dynamics model
parameters.
In order to simulate chemotherapy-induced cell death, lethally
hit cells are assumed to enter a rudimentary cell cycle leading to
apoptotic death. Cell cycle-specific, cell cycle-non specific, cell
cycle phase-specific and cell cycle phase-non specific drugs can be
simulated, as detailed in [23]. ‘‘Marking’’ of a cell as hit by the
drug is assumed to take place at the instant of drug
administration. However, its actual time of death is dictated by
the specific drug’s pharmacokinetics and pharmacodynamics.
The numbers of cells hit by the drug are computed through the
utilization of the cell kill ratio (CKR) parameter (CKR=1-cell
survival fraction), defined as the percentage of lethally hit cells
after each drug administration. A diversification of chemother-
apeutic resistance between tumor stem and non-stem cells can be
easily achieved through the use of different values of the
corresponding CKR parameters.
For a relatively short time interval compared to the tumor’s
lifetime (such as the duration of a simulated chemotherapeutic
schedule) the various cell category/phase transition rates are
considered approximately constant and reflect the means of the
actual cell category/phase transition rates over the interval.
Virtual tumor spatiotemporal initialization
A three-dimensional cubic mesh discretizing the region of
interest is considered. The elementary volume of the mesh is called
geometrical cell (GC). Each GC of the tumor accommodates
initially a number of biological cells (NBC), which is defined based
on typical solid tumor cell densities (e.g. 10
9 cells/cm
3) [27], unless
more specific information for a particular tumor is available. The
cells initially residing within each GC of the mesh are distributed
into the five classes and subclasses mentioned above. The
technique used for the tumor’s constitution initialization is critical,
in order to avoid latent artificial tumor growth behaviors, as
previously described in [23,24].
The model supports the division of tumor area into different
metabolic regions (e.g. necrotic and proliferative) based on
pertinent imaging data and the handling of each region separately.
In this case different values of specific model parameters can be
assigned to each region.
Virtual tumor spatiotemporal evolution
At each time step the discretizing mesh is scanned and the
basic cytokinetic, metabolic, pharmacokinetic/pharmacodynamic
and mechanical rules that govern the spatiotemporal evolution of
the tumor are applied. Practically, each complete scan can be
viewed as consisting of two mesh scans, as described in [23].
Briefly speaking, the first scan aims at updating the state of each
GC, by applying the rules of the cytokinetic model of Figure 1.
The second scan serves to simulate tumor expansion or
shrinkage, based on the principle that, throughout a simulation,
the total population of a GC is allowed to fluctuate between a
minimum and a maximum value, defined in relation to the initial
typical GC cell content. At each time step, checks of each GC
total population designate whether the total cell number is
above/below the predefined max/min thresholds and, if
necessary, specially-designed cell content shifting algorithms
‘‘create’’ or ‘‘delete’’ GCs and thereby lead to tumor expansion
or shrinkage, respectively.
A simplified flowchart of the entire simulation procedure is
provided as supporting material (Figure S1). A detailed description
of technical issues involved in the construction of an integrated
simulation platform incorporating image processing, visualization
and grid execution facilities will be the topic of a separate paper.
Initial presentations can be found in [26,28,29].
Clinical Trial Data for Cancer Model Adaptation
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context of the SIOP/GPOH clinical trial
A thorough study of nephroblastoma literature preceded the
simulations, so as to define -in conjunction with accumulated basic
science and clinical experience-plausible reference values and
value ranges of the various model parameters (Table 1).
A protocol of preoperative chemotherapy with a combination of
actinomycin-D and vincristine for unilateral stage I-III nephro-
blastoma tumors, treated according to the SIOP 2001/GPOH
clinical trial (Figure 2), in the framework of the ACGT project, has
been specifically simulated in the present paper.
Vincristine’s antineoplastic effect is basically attributed to its
ability to bind to the protein tubulin, thereby destroying the
functionality of the cell’s microtubules, which form the mitotic
spindle, and ultimately resulting in apoptotic cell death at mitosis
(an M-phase specific drug) [30–32]. Therefore, in the simulation
model vincristine is assumed to bind at cells at all cycling phases
and lead to apoptosis at the end of M phase. Vincristine’s toxicity
is known to decrease with increasing tumor cell density (‘‘inoculum
effect’’) [33].
Actinomycin-D is a cell cycle-nonspecific antitumor antibiotic
that binds to double-stranded DNA through intercalation between
adjacent guanine-cytosine base pairs [34]. It also acts to form toxic
oxygen-free radicals, which create DNA strand breaks, inhibiting
DNA synthesis and function. Based on the above, in the model
actinomycin-D is considered to bind to cells at all phases (including
G0) and lead to apoptosis at the end of the S phase.
The method used for the initial estimation of typical values of
the cell kill ratios of vincristine and actinomysin-D is based on
relevant pharmacokinetics and pharmacodynamics literature [35–
38] (see Text S1).
According to the SIOP 2001/GPOH clinical trial protocol,
vincristine i.v. bolus injection is directly followed by an i.v.
bolus injection of actinomycin-D, with no delay in-between. As
a first approximation, an additive drug effect of vincristine
and actinomycin-D has been assumed for all active cell cycle
phases. For dormant cells only actinomycin-D exerts a
cytotoxic effect.
Results
Cellular level-mechanisms with major impact on
nephroblastoma response to chemotherapy
The results of the sensitivity analyses performed permitted the
sorting of the model’s parameters –and hence of the correspond-
ing biological mechanisms- according to the magnitude of their
Figure 1. Generic cytokinetic model for tumor response to chemotherapy. The generic cytokinetic model used. LIMP: LImited Mitotic
Potential cells. DIFF: terminally differentiated cells. G1: Gap 1 phase. S: DNA synthesis phase. G2: Gap 2 phase. M: Mitosis. G0: dormant phase. Hit: cells
lethally hit by chemotherapy. The arrow indicating chemotherapy-induced death is a sliding arrow, with position dependent on drug
pharmacodynamics. For a definition of the depicted model parameters see Table 1.
doi:10.1371/journal.pone.0017594.g001
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mechanisms, but are governed by—and thus summarize—
various genetic determinants which may diversify the tumor
phenotype, prognosis and response to therapy for each particular
clinical case. More specifically, all model parameters pertaining
to tumor dynamics have been studied (twelve parameters in total,
see Table 1). The remaining few model parameters (see Table S1)
are miscellaneous parameters unrelated to the tumor’s dynamics.
The simulation outcome considered was the tumor volume
reduction after chemotherapy treatment, since this is a typical
measure of the response to preoperative chemotherapy treatment
in the clinical setting [19,20]. The details of the sensitivity
analysis approach adopted are presented as supporting material
(Text S2).
As shown in Figure 3, the two biological mechanisms mostly
implicated in the result of therapy are:
a. The oxygen and nutrients availability status of the tumor (as
expressed mainly by the fraction of cells entering the dormant
phase following mitosis - Psleep), and
b. The balance between the symmetric and asymmetric modes
of stem cell division, reflecting intrinsic properties of stem cells
and/or extrinsic controls from their microenvironment
(represented by the fraction of stem cells that divide
symmetrically - Psym)
Other parameters completing the picture of tumor response to
therapy, but with significantly reduced impact on the selected
outcome compared to the previous two, are:
a. The cytotoxicity of the chemotherapeutic agents (reflected by
their total cell kill ratio – CKRtotal)
b. The cell cycle duration - Tc
c. The apoptosis rate of living stem and committed progenitor
(LIMP) tumor cells - RA.
d. The fraction of the dormant cells having just left the G0
compartment that re-enter the cell cycle -PG0toG1 (which
constitutes a further way through which the oxygenation and
nutrients’ availability status of the tumor plays a role in the
model).
An additional parametric analysis is presented in Figure 4,
involving the previously defined six most critical parameters which
largely complete the picture of the tumor’s response to treatment
in terms of volume reduction (i.e. Psleep,P sym, CKRtotal,T c,R A,
PG0toG1). The combined effects of a number of parameter dyads
on the reduction percentage of a chemotherapeutically treated
tumor and on the growth rate constant characterizing its free
growth or re-growth after completion of therapy have been




Value References T1 T2 T3 T4
Tc (h) Cell cycle duration 23.0 [39] 23.0 40 23.0 55
TG0 (h) G0 (dormant phase) duration, i.e. time interval
before a dormant cell dies through necrosis
96 [40] 96 96 96 40
TN (h) Time needed for necrosis to be completed and its
lysis products to be eliminated from the tumor
20 [10,15,41] 20 20 20 120
TA (h) Time needed for apoptosis to be completed and
its products to be eliminated from the tumor
6 [42,43] 6 6 6 6
RA (h
21) Apoptosis rate of living stem and LIMP tumor cells (fraction
of non-differentiated cells dying through apoptosis per hour)
0.001 Derived from TA, based on [42,43] 0.001 0.0008 0.001 0.001
RADiff (h
21) Apoptosis rate of differentiated tumor cells per hour 0.003 0.003 0.003 0.003 0.05
RNDiff (h
21) Necrosis rate of differentiated tumor cells per hour 0.001 Derived from TN, based on [10,41] 0.001 0.001 0.001 0.05
PG0toG1 The fraction of stem or LIMP cells having just left
the G0 compartment that re-enter the cell cycle
0.01 0.01 0.01 0.01 0.01
NLIMP The maximum number of mitoses that a LIMP cell can
perform before becoming terminally differentiated
33 3 3 3
Psym Fraction of stem cells that perform symmetric division. 0.45 0.71 0.45 0.45 0.76
Psleep Fraction of cells that enter G0 phase following mitosis 0.28 0.40 0.28 0.28 0.36
CKRVCR Cell kill ratio for the specific vincristine dose 0.3 Derived based on [35,36] 0.3 0.3 0.36 0.33
CKRACT Cell kill ratio for the specific actinomycin-D dose 0.2 Derived based on [37,38] 0.2 0.2 0.34 0.22
CKRTOTAL* Combined cell kill ratio of the
two drugs (dependent parameter)
0.5 Additive drug effect considered 0.5 0.5 0.7 0.55
Definition of tumor dynamics model parameters, reference values and corresponding literature references, and values assigned for the implementation of four virtual
tumors. T1: Tumour T1, T2: Tumour T2, T3: Tumour T3, T4: Tumour T4. CKRtotal is not an independent parameter of the model.
doi:10.1371/journal.pone.0017594.t001
Figure 2. Chemotherapy treatment protocol. The simulated Wilms
tumor preoperative chemotherapy treatment protocol of the SIOP/
GPOH clinical trial.
doi:10.1371/journal.pone.0017594.g002
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TC and RA, and iii) CKRtotal and PG0toG1.
For tumor regrowth after therapy studies, an exponential free
growth pattern has been considered, which in fact approximates a
segment of the Gompertzian curve, as explained in [23]. The areas
that appear in the graphs of Figure 4 show only combinations of
biologically relevant parameter values leading to tumors that
exhibit monotonic behavior for the case of free growth [23,24] and
tumors displaying volume reduction after therapy for the case of
treatment.
Figure 4A shows the combined effect of Psym and Psleep on the
growth rate of the tumor. An intuitive observation is that a tumor
is more aggressive (with a higher growth rate constant) for higher
values of Psym and lower values of Psleep, which points out the
counteracting effect of the two mechanisms. The growth rate
‘‘isosurfaces’’ (here defined as distinct ranges of the growth rate
constant values and indicated by distinct colors) form parallel
stripes, implying that the effect of the combination of the two
parameters retains the same character over the entire value space
considered.
Figure 4C shows the combined influence of TC and RA. Virtual
tumors with prolonged cell cycle duration are less aggressive (with
a lower growth rate constant) than tumors with short cell cycle
durations. This difference becomes greater for higher values of the
spontaneous apoptosis rate. The tumor growth rate ‘‘isosurfaces’’
appear almost parallel to the axis of RA for low values of TC: the
influence of spontaneous apoptosis on the growth rate of the tumor
is much less pronounced than the effect of the cell cycle duration
(which is in accordance with the results presented in Figure 3).
In Figure 4E a biologically anticipated finding is that tumors
with higher PG0toG1 values have higher growth rate constants.
Also, as expected, the drugs’ cell kill ratio has no effect on the
tumor free growth rate; therefore, ‘‘isosurfaces’’ parallel to the axis
of the CKR parameter appear in this case.
In Figure 4B an isoline of maximum volume reduction is
discernible. A sharp decrease in the output is observed when
changing the parameter values from those that lead to that
maximum reduction, which is characteristic of the pronounced
sensitivity of the output on the values of these two parameters, in
accordance with the results of Figure 3. Parallel ‘‘isosurfaces’’ are
another characteristic of the output in this case too.
Figure 4D indicates larger volume reductions for tumors with
high values of TC and high values of RA. Finally, as shown in
Figure 4F, an increased CKR of the combination of the
chemotherapeutic agents (i.e. increased cytotoxicity) leads intui-
tively to greater tumor volume reductions. The volume reductions
are slightly higher for higher values of PG0toG1.
Clinical adaptation of the model: a proof of principle
simulated clinical case
A clinical case of nephroblastoma from the SIOP 2001/GPOH
trial has been selected and the corresponding anonymized imaging
and clinical data have been collected. The outer boundary of the
tumor based on two sets of MRI images has been provided for two
time instants, the first one corresponding to the time of diagnosis (4
days before the beginning of the chemotherapy treatment) and the
second one 3 days after the last drug administration. At this first
clinical adaptation step, the spatial distribution of macroscopically
distinct tumor subregions was not available for the particular
clinical case and therefore an equivalent tumor of the same
constitution in terms of cell categories population numbers has
been considered. Based on the imaging data, chemotherapy has
achieved tumor shrinkage equal to 73%. Post-surgery histological
data indicated a highly malignant, blastemal type of tumor, with a
regression/necrosis component after chemotherapy approximately
equal to 60% and a 100% blastemal component for the remaining
viable tumor. The available histological information for the
particular tumor has been used in the model so as to provide a
means of appropriately adjusting the corresponding populations
percentages in the equivalent homogeneous virtual tumor
considered.
Results of sensitivity analyses such as those presented in the
previous section, have provided guidance for the selection of the
model parameter values so as to succeed in implementing a virtual
tumor consistent with the actual clinical data, both in terms of
tumor volume measurements and histological constitution of the
tumor. Four virtual tumor scenarios in agreement with the tumor
Figure 3. Sorting of the model parameters according to their effect on chemotherapy-induced tumor shrinkage. Sorting of the model
parameters according to their effect on chemotherapy-induced tumor shrinkage. For a definition of the depicted model parameters see Table 1. SC:
Sorting Criterion (see Text S2).
doi:10.1371/journal.pone.0017594.g003
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values assigned to the model parameters for the implementation of
the four virtual tumor scenarios are presented in Table 1. Derived
tumor characteristics (doubling time, growth fraction etc.) and
resultant therapy-induced shrinkages are presented in Tables 2
and 3. Taking into account all the uncertainties in the medical and
literature data that have been used, Table 2 should be interpreted
as indicating approximate values of the various tumor properties.
The volume reduction for these simulated tumors is equal to
72% for T1, T2, and T3, and 73% for T4. These results are in
very good agreement with the imaging data-specified volume
shrinkage of 73%. After having initially assigned reference values
to all model parameters, exploratory perturbations have been
performed in order to achieve agreement with clinical data.
Tumor T1 has been derived by appropriately perturbing Psym and
Psleep, and tumor T2 by adjusting TC and RA. The third scenario
(T3) has been specified, by considering an initial tumor with all
parameters kept at their reference values, apart form the total cell
kill ratio, which has been adequately perturbed in order to fit the
tumor volume measurements. As will be subsequently described,
the final virtual scenario (T4) incorporates all necessary parameter
perturbations to achieve full compliance with all medical and
literature data.
Since all four virtual tumors are in good agreement with the
data in terms of tumor volume reduction, they would be
thought of as fairly good solutions of the simulation problem if
no further information was available. Nevertheless, as revealed
by the detailed tumor characteristics of these solutions, the
corresponding tumors’ subpopulation constitution and growth
rate characteristics could be highly variable. To the best of our
knowledge, all attempted adaptations of simulation models to
clinical data reported up to now in the literature involve
Figure 4. Selected combined effects of several model parameter combinations. Combined effects of selected parameter combinations on
tumor free growth rate (first column) and volume reduction after therapy (second column). Different colors correspond to distinct ranges of the
growth rate constant value or the tumor volume reduction percentage. Panels A, B: Combined effect of Psym and Psleep. Panels C,D: Combined
effect of Tc and RA. Panels E,F: Combined effect of CKRtotal and PG0toG1. For a definition of the depicted model parameters see Table 1.
doi:10.1371/journal.pone.0017594.g004
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with the exception of modeling efforts that include a distinction
between proliferating and quiescent cells [14] or oxic and
hypoxic subpopulations [15]. In sharp contrast, the presented
model, offers the possibility of a full clinical adaptation of all
available information: both imaging and histological data. Its
structure permits formulation of quantitative hypotheses regard-
ing as yet unavailable data (e.g. initial tumor subpopulations),
but which, very importantly, fulfill the constraints of the clinical
information in hand.
Tumor T4 is a scenario fully satisfying the available
histological constraints of the clinical case considered, with a
post-chemotherapy population of dead cells close to 60% (<57%)
and a quite negligible population of differentiated cells (<1%)
since a blastemal type of tumor is being studied. At the same
time, this scenario is in a rather good agreement with
nephroblastoma literature regarding those tumor characteristics
for which no clinical input was available: volume doubling time of
21 days (a range of 11–40 days is reported in literature [44–48]),
pre-chemotherapy and post-chemotherapy growth fractions
approximately equal to 37% and 30%, respectively, (correspond-
ing percentages reported in literature for nephroblastomas of
blastemal type [49]: 31–80% and 11–40%, respectively).
Notwithstanding a) that parameter values outside ranges specified
in literature could certainly not be excluded, due to both inter-
patient variability and methodological issues related to the
procedures used for their estimation, and b) that the estimated
quantitative features of the tumors are only of an approximate
character, the above observations demonstrate the basic philos-
ophy of a possible procedure towards the selection of prevailing
virtual scenarios, based on the combined use of the available for
each patient case clinical and literature data. As the available
information regarding a particular tumor’s characteristics in-
creases, further narrowing of the window of possible solutions is
to be expected. Very importantly, virtual tumor T4 satisfies
concurrently a considerable number of constraints which
drastically limit the value range of the critical model parameters
implicated in tumor response to therapy (e.g. Psym,P sleep). Our
sensitivity analyses indicate that, under all the concurrent
constraints considered, large deviations from the specified values
of these critical parameters, and hence radically different solution
characteristics, would not be expected, if an ‘‘exhaustive’’ solution
search to the particular adaptation problem was attempted.
Rather, different solutions would result mainly from alternative
Table 2. Initial virtual tumors’ characteristics.
Resultant initial tumor characteristics Typical tumor* T1 T2 T3 T4
Growth Rate Constant, k (h
21) 0.001 0.0004 0.0004 0.001 0.0014
Volume Doubling Time, Td=ln2/k (days) 29 72 72 29 21
Initial percentage of proliferating cells (Growth Fraction) (%) 14 15 19 14 37
Initial percentage of dormant cells (%) 18 36 16 18 14
Initial percentage of stem cells (%) 12 32 14 12 35
Initial percentage of LIMP cells (%) 20 19 21 20 16
Initial percentage of differentiated cells (%) 62 40 59 62 2
Initial percentage of dead cells (%) 6 9664 7
Initial tumor characteristics and volume reduction percentages for the four virtual tumor scenarios, defined by the parameter values given in Table 1. The total tumor
cell population is derived by adding the subpopulations of proliferating cells, dormant cells, differentiated cells and dead cells or, alternatively, the subpopulations of
stem cells, LIMP cells, differentiated cells and dead cells.
*The column ‘‘typical tumor’’ presents the characteristics of a tumor implemented by assigning to all model parameters their assumed reference value; it does not
constitute a solution for the simulation case considered.
doi:10.1371/journal.pone.0017594.t002
Table 3. Final virtual tumors’ characteristics and tumor volume reduction percentages.
Final tumor characteristics Typical tumor* T1 T2 T3 T4
1 day after completion of therapy 3 days after completion of therapy
Tumor volume reduction percentage (%) 56 72 72 72 73
Final percentage of proliferating cells (Growth Fraction) (%) 7 10 11 6 30
Final percentage of dormant cells (%) 13 27 11 11 12
Final percentage of stem cells (%) 7 23 8 7 29
Final percentage of LIMP cells (%) 13 14 14 10 13
Final percentage of differentiated cells (%) 74 55 73 78 1
Final percentage of dead cells (%) 6 8 5 5 57
Initial tumor characteristics and volume reduction percentages for the four virtual tumor scenarios, defined by the parameter values given in Table 1. The total tumor
cell population is derived by adding the subpopulations of proliferating cells, dormant cells, differentiated cells and dead cells or, alternatively, the subpopulations of
stem cells, LIMP cells, differentiated cells and dead cells.
*The column ‘‘typical tumor’’ presents the characteristics of a tumor implemented by assigning to all model parameters their assumed reference value; it does not
constitute a solution for the simulation case considered.
doi:10.1371/journal.pone.0017594.t003
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available data. Such an example is the NLIMP parameter, which
currently remains unspecified based on the available data; an
indication regarding the relative percentages of stem and
committed progenitor cells would restrict the range of permitted
perturbations in its value.
Bearing all this in mind, in Figure 5A the time course of the four
virtual tumors is presented. As discussed, the final tumor volume is
about the same for all tumors. Nevertheless, differences in the
evolution over time are discernible among the studied cases
(Figure 5B,C,D,E), since different tumor dynamics parameter
values lead to different initial cell subpopulations and have
implications for their evolution over time and the effect of therapy.
Numerous interesting theoretical observations could be made
based on Figure 5 (see also Figure S2); the following, though, stand
out:
N Since Psym and Psleep are the two parameters with the major
impact on the tumor’s evolution, the use of similar values for
these parameters in different virtual tumors results in quite
similar patterns of evolution over time for all cell subpopula-
tions. This is particularly evident in the case of T2 and T3
tumors (which have exactly the same values of Psym and Psleep).
N T1 and, particularly, T4 are characterized by the highest
stem cell content, as they have the highest symmetric
division fraction values. It is interesting that the currently
derived high stem cell content of T4 correlates with the high
malignancy and poor prognosis of nephroblastomas of
blastemal type, particularly so in the context of recent
reports in literature suggesting that individual tumors that
are, at the histopathological level, relatively undifferentiated
may contain higher proportions of stem cells than their more
differentiated counterparts [50]. Furthermore, recent evi-
dence suggests that within some tumors cancer stem cells
may be as numerous as the non-stem cells with which they
co-exist [50].
N T1’s high Psleep value and high TG0 value lead to a significantly
higher initial percentage of dormant cells compared to the rest
of the virtual tumors.
N T2 and T3 due their lower Psym, have higher fractions of
differentiated cells compared to T1.
N The large duration of necrosis in the case of T4 is directly
related to the large dead cell component of this tumor.
Discussion
The central focus of this work has been a thorough sensitivity
analysis of the simulation model, revealing the relative importance
of its parameters. A sorting of the parameters, and hence of the
corresponding cellular-level biological mechanisms, with major
impact on the simulation outcome has been performed. Indicative
parametric investigations that shed light on complex parameter
interrelations, which often cannot be grasped intuitively, have
been presented. The two biological mechanisms mostly implicated
in the result of therapy are the oxygenation and nutrients
availability status of the tumor and the balance between the
symmetric and asymmetric modes of stem cell division. These
results constitute part of an extensive series of such parametric
studies, aiming at deepening and advancing quantification of our
understanding of tumor response to chemotherapeutic treatment
in the nephroblastoma and, more specifically, the SIOP/GPOH
clinical trial context.
A clinical case of nephroblastoma from the SIOP 2001/
GPOH trial has been selected and by using plausible values of
the model parameters derived from clinical experience and
relevant literature, an excellent fit of the model to the available
clinical data has been achieved in terms of both volume
reduction and histological constitution of the tumor. Further-
more, derived critical tumor characteristics for which no direct
clinical information was available are in good agreement with
relevant nephroblastoma literature. Whereas various attempts of
model adaptations to volumetric data have already been reported
in the literature, agreement with clinical data in tumor
volumetric terms alone may mask tumors with radically different
characteristics. The potential to readily exploit additional data
available in the context of clinical trials, thereby narrowing the
window of possible solutions, is a particularly distinctive feature
of the ISOG model.
The fitting of the selected nephroblastoma case to the clinical
data serves as a proof of principle example, demonstrating the
basic philosophy of a possible procedure towards the selection of
prevailing virtual scenarios, based on the combined use of the
available multiscale clinical and literature data. As the available
information regarding a particular tumor’s characteristics increas-
es, further narrowing of the window of possible solutions is to be
expected. Availability of multiscale medical data imposes con-
straints on model parameter values. Conversely, after adequate
‘‘tuning’’ the simulation results could give valuable hints
concerning tumor characteristics for which actual estimations
might be missing in each case considered.
Major scientific challenge for the ISOG modeling efforts is
the eventual translation of its detailed multiscale cancer models
to clinical practice. The use of anonymized data before and after
treatment constitutes the basis for the clinical adaptation and
validation process. As more and more sets of medical data are
exploited the reliability of the model results is expected to
increase and patient-individualized modeling to be strengthened.
In future versions of the model, the individual patient’s serum
response to specific tumor antigens will be considered as well: in
the context of the ACGT project, possible correlations of the
autoantigen pattern with tumor histology (i.e. blastemal,
epithelial, and stromal cell fractions) are under investigation
[26]. Future versions of the model will also handle cases of
inhomogeneous tumors with macroscopically/metabolically dis-
tinct regions. The integrated simulation system, (incorporating
image processing, visualization, grid execution and other
technical facilities) has been termed ‘‘Oncosimulator’’ [25].
Two ‘‘oncosimulators’’ are currently being developed by ISOG,
clinically adapted and validated using real clinical trial multi-
scale data within the framework of the EC funded projects
ACGT [25] and ‘‘Contra Cancrum’’ (FP7-ICT-2007-2-223979)
[51].
It is envisaged that, at a later stage, after the completion of the
necessary adaptation and validation procedure, such simulation
platforms could support the design of new experiments or clinical
trials, by identifying important scientific questions and open
issues, brought forward through an in-depth understanding of the
system; they could even offer the potential for studying various
biological mechanisms and interactions without performing time-
consuming and costly laboratory experiments or clinical trials.
Designing some of these clinical trials or experiments is extremely
difficult, if at all feasible, as they would have to refer to the basic
science level.
In silico oncology holds much promise in the field of cancer
research. It certainly has not yet reached its full potential,
multiple challenges of diverse nature exist and many unresolved
Clinical Trial Data for Cancer Model Adaptation
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17594Clinical Trial Data for Cancer Model Adaptation
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17594issues remain to be addressed. Nevertheless, the presented
successful initial adaptation step lends support that the ISOG
modelling efforts are indeed on a viable track towards clinical
adaptation.
Supporting Information
Figure S1 Simplified flowchart of the simulation proce-
dure. Simplified flowchart of the simulation procedure. GC:
Geometrical Cell. Y:Yes, N:No.
(TIF)
Figure S2 Time evolution of various tumor subpopula-
tions. Alternative presentation of various tumor subpopulations
for the four virtual tumor scenarios implemented (T1: Tumor1,
T2: Tumor2, T3: Tumor3, T4: Tumor4, defined by the
parameter values indicated in Table 1). Time evolution of A)
proliferating, B) dead, C) terminally differentiated, D) stem, and E)
LIMP (committed progenitor) cells.
(TIF)
Table S1 Miscellaneous model parameters (unrelated to tumor
dynamics) and typical values where applicable.
(DOC)
Text S1 Calculation of reference values for the cell kill ratios of
vincristine and actinomycin-D.
(DOC)
Text S2 Details regarding sensitivity analyses.
(DOC)
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